The present invention relates to a method for extracting an oil rich in polyunsaturated fatty acids (PUFA), in particular an oil of microorganisms rich in docosahexaenoic acid (DHA, C22:6n3), in particular oils comprising more than 60% of PUFA relative to the total mass of fat.

The invention relates to preparation comprising at least one probiotic strain belonging to the genus Bacillus megaterium, and a polyunsaturated fatty acid component comprising at least one omega-3 or omega-6 fatty acid selected from eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), arachidonic acid (ARA), alpha linolenic acid, stearidonic acid, eicosatetraenoic acid, docosapentaenoic acid, linoleic acid, γ-linolenic acid, wherein the polyunsaturated fatty acid component comprises an omega-3 or omega-6 fatty acid salt. The invention further relates to use of the inventive preparation as a feed or food supplement, pharmaceutical product, feed-or foodstuff compositions and for topical applications.

The invention relates to preparation comprising at least one probiotic strain belonging to the genus Bacillus megaterium, and a polyunsaturated fatty acid component comprising at least one omega-3 or omega-6 fatty acid selected from eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), arachidonic acid (ARA), alpha linolenic acid, stearidonic acid, eicosatetraenoic acid, docosapentaenoic acid, linoleic acid, γ-linolenic acid, wherein the polyunsaturated fatty acid component comprises an omega-3 or omega-6 fatty acid salt. The invention further relates to use of the inventive preparation as a feed or food supplement, pharmaceutical product, feed-or foodstuff compositions and for topical applications.

Compositions may be used for a variety of therapeutic applications, including treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, such as aging or stress, diabetes, obesity, and neurodegenerative diseases. The compositions can be administered to an older adult or an elderly individual. It can also be administered to a patient in ICU. The compositions contain a combination of curcumin and an omega-3 fatty acid. The compositions can be food products, nutritional supplements or nutraceutical. The compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.

Compositions may be used for a variety of therapeutic applications, including treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, such as aging or stress, diabetes, obesity, and neurodegenerative diseases. The compositions can be administered to an older adult or an elderly individual. It can also be administered to a patient in ICU. The compositions contain a combination of curcumin and an omega-3 fatty acid. The compositions can be food products, nutritional supplements or nutraceutical. The compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.

This invention relates to methods for treating dry eye and improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands of a mammal, comprising the steps of administering a composition consisting essentially of an effective amount of omega-3 fatty acids on a daily dosage basis to the mammal having inflamed or dysfunctional meibomian glands, wherein the effective amount of omega-3 fatty acids comprises eicosapentaenoic acid (EPA) in an amount greater than 600 mg and in the re-esterified triglyceride form, and wherein the composition administered does not include any additional omega-6 fatty acids beyond the range normally found in the source material of the omega-3 fatty acids. The composition administered may facilitate an increase in levels of anti-inflammatory omega-3's in the meibum composition of the treated meibomian glands of the mammal and a decrease in the levels of inflammatory omega-6's in the meibum composition of the treated meibomian glands. The method of administering the composition of the present invention consisting essentially of omega-3 fatty acids may further comprise (1) the steps of taking a baseline measurement of tear break up time of the mammal prior to administering the composition and taking a second measurement of tear break up time of the treated mammal after administration of the composition to evaluate the improvement in tear break up time of the mammal as compared to the corresponding baseline measurement, (2) the steps of taking a baseline measurement of tear osmolarity of the mammal prior to administering the composition and taking a second measurement of tear osmolarity of the mammal after administration of the composition to evaluate the reduction of tear osmolarity of the mammal as compared to the corresponding baseline measurement and/or (3) the steps of taking a baseline measurement of the quality of tears of the mammal prior to administering the composition and taking a second measurement of the quality of tears of the mammal after administration of the composition to evaluate the improvement in the quality of tears of the mammal as compared to the corresponding baseline measurement.

This invention relates to methods for treating dry eye and improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands of a mammal, comprising the steps of administering a composition consisting essentially of an effective amount of omega-3 fatty acids on a daily dosage basis to the mammal having inflamed or dysfunctional meibomian glands, wherein the effective amount of omega-3 fatty acids comprises eicosapentaenoic acid (EPA) in an amount greater than 600 mg and in the re-esterified triglyceride form, and wherein the composition administered does not include any additional omega-6 fatty acids beyond the range normally found in the source material of the omega-3 fatty acids. The composition administered may facilitate an increase in levels of anti-inflammatory omega-3's in the meibum composition of the treated meibomian glands of the mammal and a decrease in the levels of inflammatory omega-6's in the meibum composition of the treated meibomian glands. The method of administering the composition of the present invention consisting essentially of omega-3 fatty acids may further comprise (1) the steps of taking a baseline measurement of tear break up time of the mammal prior to administering the composition and taking a second measurement of tear break up time of the treated mammal after administration of the composition to evaluate the improvement in tear break up time of the mammal as compared to the corresponding baseline measurement, (2) the steps of taking a baseline measurement of tear osmolarity of the mammal prior to administering the composition and taking a second measurement of tear osmolarity of the mammal after administration of the composition to evaluate the reduction of tear osmolarity of the mammal as compared to the corresponding baseline measurement and/or (3) the steps of taking a baseline measurement of the quality of tears of the mammal prior to administering the composition and taking a second measurement of the quality of tears of the mammal after administration of the composition to evaluate the improvement in the quality of tears of the mammal as compared to the corresponding baseline measurement.

Embodiments of a method of purifying a lysophosphatidylcholine (e.g., LPC-DHA and/or LPC-EPA) from a composition containing the lysophosphatidylcholine and at least one impurity, e.g., from phospholipids, free fatty acids, triacylglycerols (TAGs), diacylglycerols (DAGs), monoacylglycerols (MAGs), glycerol, sterols, tocopherols, vitamin A, flavonoids, and minerals can use a continuous simulated moving bed process, a batch column chromatography method, or a single column to provide a purified composition of the lysophosphatidylcholine. The purified lysophosphatidylcholine (e.g., LPC-DHA and/or LPC-EPA) products can be used in various pharmaceutical and nutraceutical applications, e.g., for treating and/or preventing a neurological disease or disorder.

A composition for use as antioxidant, where the composition has at least one polyunsaturated fatty acid component and at least one anthocyanin component. The polyunsaturated fatty acid component is an amino acid salt of the omega-3 fatty acids eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA). The anthocyanin component is cyanidin-3-glucoside, delphinidin-3-glucoside, malvidin-3-galactoside, peonidin-3-galactoside, or malvidin-3-glucoside. A method for treating a disease with the composition. A method of providing an antioxidant to a subject with the composition.

A composition for use as antioxidant, where the composition has at least one polyunsaturated fatty acid component and at least one anthocyanin component. The polyunsaturated fatty acid component is an amino acid salt of the omega-3 fatty acids eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA). The anthocyanin component is cyanidin-3-glucoside, delphinidin-3-glucoside, malvidin-3-galactoside, peonidin-3-galactoside, or malvidin-3-glucoside. A method for treating a disease with the composition. A method of providing an antioxidant to a subject with the composition.